Should ivonib (ivitinib) be taken for life?

Ivosidenib (Ivosidenib), as a potent oral targeted inhibitor against isocitrate dehydrogenase-1 (IDH1) mutations, has brought new treatment hope to many cancer patients. However, the answer to the question of whether ivonib needs to be taken for life is not fixed.

First of all, the use of ivonib is based on the patient's specific condition and the doctor's recommendation. Avosidenib can significantly extend survival and improve quality of life in patients with relapsed or refractory acute myeloid leukemia (AML) and certain advanced metastatic cholangiocarcinomas. But this does not mean that all patients need or should take this drug for life.

In actual treatment, doctors will regularly evaluate the patient's condition and drug response. If ivosidenib has a positive impact on a patient's condition and no serious side effects occur, treatment may be continued for a while. However, if your condition is in remission or stable, your doctor may consider reducing the dose or discontinuing the medication to avoid unnecessary drug exposure and potential side effects.

In addition, ivosidenib is not suitable for all cancer patients. It is mainly targeted at patients carrying IDH1 mutations. In patients without this mutation, ivosidenib may be less effective or ineffective.

In summary, whether ivonib needs to be taken for life depends on many factors, including the patient's specific condition, drug response, and doctor's advice. Therefore, patients should communicate closely with their doctors while taking ivonib and adjust their treatment plan according to changes in their condition and doctor's recommendations. At the same time, patients should also pay attention to observing their body's reactions and promptly report any discomfort or abnormal symptoms to the doctor to ensure the safety and effectiveness of treatment.